A multicentre parallel-group randomised trial assessing multiparametric MRI characterisation and image-guided biopsy of prostate in men suspected of having prostate cancer: MULTIPROS study protocol

Magdalena Szewczyk-Bieda, Cheng Wei, Katherine Coll, Stephen Gandy, Peter Donnan, Senthil Kumar Arcot Ragupathy, Paras Singh, Jennifer Wilson, Ghulam Nabi (Lead / Corresponding author)

Research output: Contribution to journalArticle

29 Downloads (Pure)

Abstract

Background: There is growing evidence suggesting that multiparametric magnetic resonance imaging (mpMRI) is a marker for prostate cancer (PCa) aggressiveness and could be used to plan treatment. Improving early detection of clinically significant PCa with pre-biopsy mpMRI would very likely have advantages including optimising the diagnosis and treatment of diseases and diminishing patient anxiety.

Methods and materials: This is a prospective multicentre study of pre-biopsy mpMRI diagnostic test accuracy with subgroup randomisation at a 1:1 ratio with respect to transrectal ultrasound (TRUS) and MRI/US fusion-guided biopsy or TRUS-only biopsy. It is designed as a single-gate study with a single set of inclusion criteria. The total duration of the recruitment phase was 48 months; however, this has now been extended to 66 months. A sample size of 600 participants is required.

Discussion: The primary objective is to determine whether mpMRI can improve PCa detection and characterisation. The key secondary objective is to determine whether MRI/US fusion-guided biopsy can reduce the number of false-negative biopsies. Ethical approval was obtained from the East of Scotland Research Ethics Committee 1 (14/ES/1070) on 20 November 2014. The results of this study will be used for publication and presentation in national and international journals and at scientific conferences.

Trial registration: ClinicalTrials.gov, NCT02745496. Retrospectively registered on 20 April 2016.

Original languageEnglish
Article number638
Pages (from-to)1-8
Number of pages8
JournalTrials
Volume20
DOIs
Publication statusPublished - 21 Nov 2019

Fingerprint

Image-Guided Biopsy
Prostate
Prostatic Neoplasms
Biopsy
Magnetic Resonance Imaging
Research Ethics Committees
Scotland
Random Allocation
Routine Diagnostic Tests
Sample Size
Multicenter Studies
Publications
Anxiety
Prospective Studies
Therapeutics

Keywords

  • Prostate cancer
  • Multiparametric magnetic resonance imaging
  • Prostate biopsy

Cite this

@article{85e8863ada404fc89d6db53badb86e2a,
title = "A multicentre parallel-group randomised trial assessing multiparametric MRI characterisation and image-guided biopsy of prostate in men suspected of having prostate cancer: MULTIPROS study protocol",
abstract = "Background: There is growing evidence suggesting that multiparametric magnetic resonance imaging (mpMRI) is a marker for prostate cancer (PCa) aggressiveness and could be used to plan treatment. Improving early detection of clinically significant PCa with pre-biopsy mpMRI would very likely have advantages including optimising the diagnosis and treatment of diseases and diminishing patient anxiety.Methods and materials: This is a prospective multicentre study of pre-biopsy mpMRI diagnostic test accuracy with subgroup randomisation at a 1:1 ratio with respect to transrectal ultrasound (TRUS) and MRI/US fusion-guided biopsy or TRUS-only biopsy. It is designed as a single-gate study with a single set of inclusion criteria. The total duration of the recruitment phase was 48 months; however, this has now been extended to 66 months. A sample size of 600 participants is required.Discussion: The primary objective is to determine whether mpMRI can improve PCa detection and characterisation. The key secondary objective is to determine whether MRI/US fusion-guided biopsy can reduce the number of false-negative biopsies. Ethical approval was obtained from the East of Scotland Research Ethics Committee 1 (14/ES/1070) on 20 November 2014. The results of this study will be used for publication and presentation in national and international journals and at scientific conferences.Trial registration: ClinicalTrials.gov, NCT02745496. Retrospectively registered on 20 April 2016.",
keywords = "Prostate cancer, Multiparametric magnetic resonance imaging, Prostate biopsy",
author = "Magdalena Szewczyk-Bieda and Cheng Wei and Katherine Coll and Stephen Gandy and Peter Donnan and Ragupathy, {Senthil Kumar Arcot} and Paras Singh and Jennifer Wilson and Ghulam Nabi",
year = "2019",
month = "11",
day = "21",
doi = "10.1186/s13063-019-3746-0",
language = "English",
volume = "20",
pages = "1--8",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central",

}

A multicentre parallel-group randomised trial assessing multiparametric MRI characterisation and image-guided biopsy of prostate in men suspected of having prostate cancer : MULTIPROS study protocol. / Szewczyk-Bieda, Magdalena; Wei, Cheng; Coll, Katherine; Gandy, Stephen; Donnan, Peter; Ragupathy, Senthil Kumar Arcot; Singh, Paras; Wilson, Jennifer; Nabi, Ghulam (Lead / Corresponding author).

In: Trials, Vol. 20, 638, 21.11.2019, p. 1-8.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A multicentre parallel-group randomised trial assessing multiparametric MRI characterisation and image-guided biopsy of prostate in men suspected of having prostate cancer

T2 - MULTIPROS study protocol

AU - Szewczyk-Bieda, Magdalena

AU - Wei, Cheng

AU - Coll, Katherine

AU - Gandy, Stephen

AU - Donnan, Peter

AU - Ragupathy, Senthil Kumar Arcot

AU - Singh, Paras

AU - Wilson, Jennifer

AU - Nabi, Ghulam

PY - 2019/11/21

Y1 - 2019/11/21

N2 - Background: There is growing evidence suggesting that multiparametric magnetic resonance imaging (mpMRI) is a marker for prostate cancer (PCa) aggressiveness and could be used to plan treatment. Improving early detection of clinically significant PCa with pre-biopsy mpMRI would very likely have advantages including optimising the diagnosis and treatment of diseases and diminishing patient anxiety.Methods and materials: This is a prospective multicentre study of pre-biopsy mpMRI diagnostic test accuracy with subgroup randomisation at a 1:1 ratio with respect to transrectal ultrasound (TRUS) and MRI/US fusion-guided biopsy or TRUS-only biopsy. It is designed as a single-gate study with a single set of inclusion criteria. The total duration of the recruitment phase was 48 months; however, this has now been extended to 66 months. A sample size of 600 participants is required.Discussion: The primary objective is to determine whether mpMRI can improve PCa detection and characterisation. The key secondary objective is to determine whether MRI/US fusion-guided biopsy can reduce the number of false-negative biopsies. Ethical approval was obtained from the East of Scotland Research Ethics Committee 1 (14/ES/1070) on 20 November 2014. The results of this study will be used for publication and presentation in national and international journals and at scientific conferences.Trial registration: ClinicalTrials.gov, NCT02745496. Retrospectively registered on 20 April 2016.

AB - Background: There is growing evidence suggesting that multiparametric magnetic resonance imaging (mpMRI) is a marker for prostate cancer (PCa) aggressiveness and could be used to plan treatment. Improving early detection of clinically significant PCa with pre-biopsy mpMRI would very likely have advantages including optimising the diagnosis and treatment of diseases and diminishing patient anxiety.Methods and materials: This is a prospective multicentre study of pre-biopsy mpMRI diagnostic test accuracy with subgroup randomisation at a 1:1 ratio with respect to transrectal ultrasound (TRUS) and MRI/US fusion-guided biopsy or TRUS-only biopsy. It is designed as a single-gate study with a single set of inclusion criteria. The total duration of the recruitment phase was 48 months; however, this has now been extended to 66 months. A sample size of 600 participants is required.Discussion: The primary objective is to determine whether mpMRI can improve PCa detection and characterisation. The key secondary objective is to determine whether MRI/US fusion-guided biopsy can reduce the number of false-negative biopsies. Ethical approval was obtained from the East of Scotland Research Ethics Committee 1 (14/ES/1070) on 20 November 2014. The results of this study will be used for publication and presentation in national and international journals and at scientific conferences.Trial registration: ClinicalTrials.gov, NCT02745496. Retrospectively registered on 20 April 2016.

KW - Prostate cancer

KW - Multiparametric magnetic resonance imaging

KW - Prostate biopsy

U2 - 10.1186/s13063-019-3746-0

DO - 10.1186/s13063-019-3746-0

M3 - Article

C2 - 31752954

VL - 20

SP - 1

EP - 8

JO - Trials

JF - Trials

SN - 1745-6215

M1 - 638

ER -